Pfizer said three small doses of its vaccine offers strong protection to youngsters under 5, according to preliminary data.
That news comes a month after Moderna said it would But a few steps remain before the shots are available. Health officials and their expert panels must first decide they are safe enough and provide enough protection to authorize them.U.S. Food and Drug Administration vaccine chief Dr. Peter Marks has pledged the agency will “move quickly without sacrificing our standards” in evaluating tot-sized doses from both Pfizer and Moderna.
The FDA has tentatively set a June 15 date for its scientific advisers to publicly review the two companies’ vaccines. After the advisers weigh in, the FDA determines whether to authorize the shot. Moderna is seeking clearance for two low-dose shots for children under age 6 while Pfizer hopes to offer three extra-low doses to kids under age 5 — differences due to how each company studied its vaccine. Currently the U.S. recommends vaccinations for everyone age 5 and older, and Pfizer is the only option for those children. Moderna for now is used only in adults in the U.S.
The CDC would convene its own panel of advisers to debate the recommendation before issuing its official guidance.The Biden administration has said the shots will roll out rapidly, and most tots are expected to be vaccinated in pediatricians’ offices or health clinics. It’s not clear how much demand there will be to vaccinate the youngest kids, however. Pfizer shots for 5- to 11-year-olds opened in November, but only about 30% of that age group have gotten the recommended initial two doses.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Three-dose Covid-19 vaccine produces strong immune response in young children, Pfizer and BioNTech sayThree child-size doses of the Pfizer/BioNTech Covid-19 vaccine appeared to be safe and showed a strong immune response in children ages 6 months to 5 years, the companies said Monday. The vaccine makers said they will finish submitting the trial data to the US Food and Drug Administration this week.
Read more »
Pfizer: 3 COVID-19 shots protect children under 5Pfizer says three small doses of its COVID-19 vaccine protect children under the age of 5 and that it plans to give the data to U.S. regulators later this week.
Read more »
COVID-19 vaccine for kids under 5: Pfizer says 3 small doses offer strong protectionPfizer says it plans to give the data to U.S. regulators later this week. The 18 million tots under 5 are the only group in the U.S. not yet eligible for COVID-19 vaccination.
Read more »
Pfizer says its COVID-19 vaccine produces a strong immune response in kids under 5A third pediatric dose of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to under 5 years of age prompted a strong immune response, with a safety profile that was similar to placebo, the companies said:
Read more »
U.S. FDA sets June meeting dates for Moderna, Pfizer small children COVID-19 vaccinesThe U.S. Food and Drug Administration set June 14-15 as the new meeting date to review Moderna Inc's emergency authorization request for its COVID-19 vaccine for children aged 6 months to 5 years and Pfizer Inc's vaccine for those aged 6 months through 4 years.
Read more »
Pfizer Says Their COVID-19 Vaccine For Kids Under 5 Is 80% Effective Against OmicronPfizer said in preliminary findings in a subset of a clinical trial indicate that 3 doses of the vaccine are 80% effective in preventing symptomatic infection.
Read more »